About James L Wynn
Dr. James Wynn is a Professor of Pediatrics and Pathology, Immunology, and Experimental Medicine. He earned his medical degree and completed his clinical training in Pediatrics and Neonatal-Perinatal Medicine at the University of Florida (2002-2008). He served as faculty at Duke University and Vanderbilt University before joining UF Health in July of 2015. His research program centers on the investigation of sepsis in newborn and premature infants. He is a principle investigator on three active NIH R01 awards (2 clinical; 1 basic science). He has published over 100 peer-reviewed manuscripts, reviews, book chapters, and editorials. He has served as reviewer for the NIH, the Bill and Melinda Gates Foundation, USAID, and over 35 scientific journals, including Pediatric Research where he was an associate editor from 2016-2022. He has mentored over 20 trainees ranging from undergraduate to post-doctoral level.
Neonatal – Perinatal MedicineAmerican Board of Pediatrics
- Neonatal-Perinatal Medicine
- Neonatal sepsis
The Wynn laboratory (http://wynn.research.pediatrics.med.ufl.edu) is focused on the investigation of neonatal-specific innate immune cellular function and inflammatory signaling during sepsis as well as development of novel therapeutic immunomodulatory strategies aimed at improving sepsis outcomes. Sepsis represents a significant clinical problem in the developmentally immature preterm neonate where attack rates may reach 60 percent with a 40 percent rate of death/major disability in developed countries. We employ both preclinical mechanistic investigations in association with observational human studies to improve our understanding of the neonatal-specific host response to sepsis. We use a wide variety of molecular and genetic techniques to interrogate the immune response via in vivo, ex vivo, and in vitro approaches. Applications of our work include improving the accuracy of sepsis diagnostic methods, identification of prognostic and clinical stratification markers, and discovery of potential opportunities for translational interventions aimed at improving infection-related outcomes.
- Neonatal Sepsis